neostigmine has been researched along with Graves Disease in 2 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of this study was to investigate the frequency of association between Myasthenia Gravis (MG) and Graves Ophthalmopathy (GO) using the responses to diagnostic tests for MG (fatigue and neostigmine tests) by measuring horizontal saccadic eye movements (SEM)." | 9.08 | [Analysis of ocular saccadic movements with a fatigue test and neostigmine in Graves' ophthalmopathy]. ( Di Costanzo, A; di Lorenzo, L; Dorato, M; Gigante, M; Savastano, S; Scarpitta, MT, 1997) |
| "Aim of this study was to investigate the frequency of association between Myasthenia Gravis (MG) and Graves Ophthalmopathy (GO) using the responses to diagnostic tests for MG (fatigue and neostigmine tests) by measuring horizontal saccadic eye movements (SEM)." | 5.08 | [Analysis of ocular saccadic movements with a fatigue test and neostigmine in Graves' ophthalmopathy]. ( Di Costanzo, A; di Lorenzo, L; Dorato, M; Gigante, M; Savastano, S; Scarpitta, MT, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Recordier, AM | 1 |
| Aubert, L | 1 |
| Arroyo, H | 1 |
| Paecht, A | 1 |
| Cabot, J | 1 |
| di Lorenzo, L | 1 |
| Savastano, S | 1 |
| Di Costanzo, A | 1 |
| Scarpitta, MT | 1 |
| Gigante, M | 1 |
| Dorato, M | 1 |
1 trial available for neostigmine and Graves Disease
| Article | Year |
|---|---|
[Analysis of ocular saccadic movements with a fatigue test and neostigmine in Graves' ophthalmopathy].
Topics: Adult; Cholinesterase Inhibitors; Fatigue; Female; Graves Disease; Humans; Male; Middle Aged; Neosti | 1997 |
1 other study available for neostigmine and Graves Disease
| Article | Year |
|---|---|
[Priapism during treatment of Basedow's disease].
Topics: Adult; Drug Synergism; Eye Manifestations; Graves Disease; Humans; Male; Neostigmine; Pyridostigmine | 1966 |